Search

Copyright of Technical Transactions / Czasopismo Techniczne is the property of Sciendo and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

We compared initial computed tomography (CT) and positron emission tomography (PET)/CT in 96 patients with Hodgkin lymphoma (HL), assessing the role of baseline PET/CT in stage migration and treatment selection. The number of patients with stage I, II, III and IV disease based on CT versus PET/CT was: 5 vs. 7, 49 vs. 37, 28 vs. 22 and 14 vs. 30, respectively. In 33 (34%) patients, PET/CT changed HL stage: 27 (28%) were upstaged and six (6.3%) downstaged. Upstaging was caused by detection of new extranodal involvements (47 sites in 26 patients): bone marrow (10 patients), spleen (five patients) and lung (two patients). In nine patients ≥ 2 further coexisting locations were detected. Downstaging resulted from the absence of fluorodeoxyglucose (18F-FDG) uptake in enlarged nodes (> 15 mm) in the abdomen and pelvis. PET/CT modified HL stage in 34% of patients leading to treatment modification in the majority. Our results indicate that PET/CT should be mandatory in the initial staging of HL. [ABSTRACT FROM AUTHOR]

Copyright of Dermatology Review / Przeglad Dermatologiczny is the property of Termedia Publishing House and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

A letter to the editor is presented which discusses treating Hodgkin lymphoma patients who are resistant to ABVD chemotherapy regime by BEACOPP chemotherapy regime and it also include patients resistant to BEACOPP intensification and resistant to other chemotherapy treatments.

The incidence of head and neck cancer (HNC) which is the seventh most common cancer worldwide, continues to rise due to tobacco-derived carcinogens, excessive alcohol consumption, and common infection with oncogenic strains of human papillomavirus (HPV) [1,2]. The steady increase in the number of HPV-related oropharyngeal cancers makes the landscape of HNC more heterogeneous. Radiation therapy (RT) remains the mainstay of treatment as a sole modality, in combination with chemotherapy (chemoradiotherapy, CRT) or adjuvant after surgery. However, reliable predictive markers of response to conventional RT or CRT have not been found, despite established knowledge about the predictors of checkpoint inhibitors in metastatic disease. In view of the unsatisfactory results of clinical trials using concurrent RT/CRT with immunotherapy, increasing attention is being paid to the local effects of RT on the tumor microenvironment and systemic immune response. We hypothesized that the baseline expression of programmed death 1 ligand (PD-L1) and intratumoral infiltration with CD8+ lymphocytes (TILsCD8+) score in the non-metastatic oral cavity (OC) and oro-/hypopharynx (PX) cancers may correlate with RT response. It was a retrospective single-center analysis involving OC and PX patients who underwent radical RT (66Gy prescribed to the primary tumor, given in 30 fx/6 weeks) with or without concurrent chemotherapy (Cisplatin 100 mg/m2 i.v. every three weeks or 40 mg/m2 i.v weekly). We performed analysis of TILsCD8+ and PD-L1 expression status in the archival biospecimens of the treatment-naïve primary tumor. Tissue microarrays (TMA) were prepared using the Manual Tissue Arrayer MTA-1 (Beecher Instruments, Inc., USA). The TMA sections were first stained with hematoxylin and eosin to verify the invasive neoplastic content within each core. Next, consecutive sections were stained with IVD-grade antibodies, anti-PD-L1 (SP263) and anti-CD8 (SP57). PD-L1 expression was assessed in tumor cells, as TPS. For statistical analysis, the patients were divided into three groups: consistently negative (all cores with no positive cells), heterogeneous, and consistently PD-L1 high (const-high, all cores with >30% positive cells). Next, for each patient, the mean number of TILsCD8 per 1.76 mm2 of invasive tumor was calculated and recorded semi-quantitatively. Scores of <5, 6–50, 51–199, and ≥200 lymphocytes per core were rated as immunoscores (IMs) of 0, 1, 2, and 3, respectively. For statistical analyses, patients were divided into two groups: TILsCD8-negative (IM = 0) and TILsCD8-positive (IM ≥ 1). [Display omitted] The study group was compromised of 61 patients (OC, n=33; PX, n=28). The cumulative 5-year overall survival (5YOS) rate was 57.58% and 64.29%, respectively. Patients were treated between 2012 and 2018, postoperatively (PORT; n=26) or qualified for definitive CRT (n=35). HPV-positive cancers accounted for 3% of OC and 54% of PX. In the OC and PX groups, more patients were PD-L1 negative, 57% and 67%, respectively (Table 1). The univariate analysis showed no influence of PD-L1 expression values on long-term survival. However, the survival curves of patients with PX and PD-L1 expression ≥1% vs. <1% visibly separate (p=0.18) (Figure 1). Most of the examined patients with OC showed a positive TILsCD8 score, with longer 5YOS compared to patients with score 0, however the difference did not reach statistical significance (OC - 48.3% vs 25%; p=0.65). [Display omitted] In our analysis, no association of PD-L1 expression and TILsCD8+ score, and patient outcome can be found. In univariate analysis we did not find any predictive factors for RT response. The main limitation of our study was very small group sizes. [ABSTRACT FROM AUTHOR]

Aim of the Study: Cancer is usually associated with impaired nutritional status, which is one of the factors contributing to the deterioration of the results of surgery, chemotherapy, or radiotherapy. The aim of this study was the assessment of the nutritional status of patients with CRC qualified to chemotherapy., Material and Methods: Seventy-five persons aged 40-86 years with colorectal cancer were examined. To evaluate the nutritional status NRS 2002, SGA, SCRINIO Working Group classification, VAS scale for appetite, and FAACT questionnaire were used. The health status of patients was evaluated based on the Karnofsky Performance Scale. Anthropometric measurements were made., Results: The results indicate that 75% of patients present pre-cachexia status based on SCRINIO Working Group classification. According to both NRS-2002 and SGA, 73.3% of patients were moderately malnourished and 2.7% were severely malnourished. 37.0% of patients had moderate appetite and 6.0% ( n = 5) had poor appetite. The Karnofsky score indicates the state of normal activity, and minor signs and symptoms of the disease among most of the patients. A statistically significant positive correlation was found between the VAS and the Karnofsky score (R = 0,4; p < 0.05). The FACCT average score (78.5) indicates a reduction in the quality of life of the patients in all aspects of functioning., Conclusions: Evaluation of the baseline nutritional status of patients with CRC should be a part of routine clinical practice. Because of the high incidence of confirmed pre-cachexia, this group of patients also requires early adequate nutrition intervention., Competing Interests: The authors declare no conflict of interest.

Apical lung location of lymphomas is extremely rare and may pose diagnostic problems. Here we present a case of advanced primary Pancoast-like left apical lung lymphoma incidentally diagnosed in a 72 year old asymptomatic woman after a routine, prophylactic chest X-ray performed in June 2005. FNB was not diagnostic therefore an open lung biopsy was attempted. Histopathological examination of the excised specimen was consistent with B-cell low-grade marginal zone extranodal NHL (BALTL); CD20+, CD3-. Treatment combined of 9 cycles of chemotherapy followed by radiotherapy of the residual mass allowed to achieve a long-term complete remission.